Get the Stockscreener App
1.29
5.84%
-0.08
After Hours:
1.29
Citius Pharmaceuticals Inc stock is traded at $1.29, with a volume of 310.44K.
It is down -5.84% in the last 24 hours and down -32.11% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$1.37
Open:
$1.31
24h Volume:
310.44K
Relative Volume:
0.13
Market Cap:
$13.72M
Revenue:
-
Net Income/Loss:
$-39.14M
P/E Ratio:
-0.2161
EPS:
-5.97
Net Cash Flow:
$-28.20M
1W Performance:
-22.75%
1M Performance:
-32.11%
6M Performance:
-52.04%
1Y Performance:
-94.30%
1-Day Range:
$1.26
$1.333
1-Week Range:
$1.26
$1.71
52-Week Range:
$0.65
$26.25
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.29 | 15.31M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
How does Citius Pharmaceuticals Inc. compare to its industry peersFree Stock Watchlist For Fast Growth - jammulinksnews.com
Why is Citius Pharmaceuticals Inc. stock attracting strong analyst attentionBreakout Stocks Signals For Fast Growth - jammulinksnews.com
What are the technical indicators suggesting about Citius Pharmaceuticals Inc.Chart Pattern Trend Scanner With Low Risk - jammulinksnews.com
Is Citius Pharmaceuticals Inc. reversing from oversold territoryIntraday Trend Analysis for Fast Gains Released - metal.it
What makes Citius Pharmaceuticals Inc. stock price move sharplyConsistent Profit Pattern Recognition Tools Shared - beatles.ru
Citius Pharmaceuticals Inc. Chart Enters High Volatility ZoneCommunity Entry Consensus Trade Ideas Shared - metal.it
Wyckoff Accumulation Phase Possible in Citius Pharmaceuticals Inc.Weekly Chart Analysis With Entry Advice Provided - metal.it
When is Citius Pharmaceuticals Inc. stock expected to show significant growthFree Stock Tracker With Low Risk - jammulinksnews.com
Is Citius Pharmaceuticals Inc. stock overvalued or undervaluedRapid portfolio appreciation - jammulinksnews.com
What is the dividend policy of Citius Pharmaceuticals Inc. stockConsistently high yield - jammulinksnews.com
Is it the right time to buy Citius Pharmaceuticals Inc. stockInvest smarter with expert trading signals - jammulinksnews.com
What is the risk reward ratio of investing in Citius Pharmaceuticals Inc. stockBreakout profit opportunities - jammulinksnews.com
What are analysts’ price targets for Citius Pharmaceuticals Inc. in the next 12 monthsDiscover breakthrough stocks with expert help - jammulinksnews.com
How Citius Pharmaceuticals Inc. stock performs during market volatilityFree Stock Trading Signals - metal.it
Is Citius Pharmaceuticals Inc. a good long term investmentExtraordinary profit generation - PrintWeekIndia
What analysts say about Citius Pharmaceuticals Inc. stockFree Investment Community - PrintWeekIndia
Citius Pharmaceuticals Inc. Stock Analysis and ForecastLightning-fast growth - Autocar Professional
Citius Oncology Announces Closing of $9.0 Million Public Offering - StreetInsider
What drives Citius Pharmaceuticals Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Citius Oncology shares rise 1.31% after-hours after closing a $9.0 million public offering. - AInvest
Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia
Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest
Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):